Clopidogrel for smokers and aspirin for nonsmokers?: not so fast.
New data solidify a "smoker's paradox" for clopidogrel, with current smokers appearing to respond better than nonsmokers. However, the clinical implications of this finding are unclear. This Commentary discusses the new data and puts it into clinical context.